Deborah Grady
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Deborah Grady has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
George F. Sawaya
3 shared publicationsMargaret Kristof
3 shared publicationsElizabeth Barrett-Connor
2 shared publications- Jane A. Cauley
Department of Epidemiology, School of Public Health, University of Pittsburgh , Pittsburgh, PA 15261
2 shared publications Jingli Song
2 shared publicationsMary Tagliaferri
2 shared publications
Latest Publications
- 1 June 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (6) , 854
Inappropriate Use of Steroids for Acute Respiratory Infection
This Viewpoint discusses the lack of benefit and possible harms in treating acute respiratory infections with systemic steroids.
- 1 June 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (6) , 854
Inappropriate Use of Steroids for Acute Respiratory Infection
This Viewpoint discusses the lack of benefit and possible harms in treating acute respiratory infections with systemic steroids.
- Open Access
- 1 March 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (3) , 413-+
The Electronic Health Record as Practice-Improvement Coach
Unnecessary diagnostic imaging is a prevalent form of medical overuse, and leads to unnecessary invasive procedures, radiation exposure, emotional stress, and n
- 1 March 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (3) , 413-+
Open AccessThe Electronic Health Record as Practice-Improvement Coach
Unnecessary diagnostic imaging is a prevalent form of medical overuse, and leads to unnecessary invasive procedures, radiation exposure, emotional stress, and n
- Open Access
- 1 February 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (2) , 185-186
Evidence for Postmenopausal Hormone Therapy to Prevent Chronic Conditions
In the current issue of JAMA, the US Preventive Services Task Force reiterates and updates their recommendation that asymptomatic postmenopausal women should no
- 1 February 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (2) , 185-186
Open AccessEvidence for Postmenopausal Hormone Therapy to Prevent Chronic Conditions
In the current issue of JAMA, the US Preventive Services Task Force reiterates and updates their recommendation that asymptomatic postmenopausal women should no
- Open Access
- 1 February 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (2) , 187
Quality Improvement for Quality Improvement Studies
At JAMA Internal Medicine, we receive many manuscripts describing studies designed to improve health care quality, safety, or value. We applaud these efforts, a
- 1 February 2018
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (2) , 187
Open AccessQuality Improvement for Quality Improvement Studies
At JAMA Internal Medicine, we receive many manuscripts describing studies designed to improve health care quality, safety, or value. We applaud these efforts, a
- Open Access
- 1 August 2017
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 177 (8) , 1207
Routine Laboratory Tests in Hospitalized Patients—The Registered Nurse’s Role
- 1 August 2017
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 177 (8) , 1207
Open AccessRoutine Laboratory Tests in Hospitalized Patients—The Registered Nurse’s Role
- 1 May 2010
- Published by Elsevier in The American Journal of Medicine
- Vol. 123 (5) , 469.e1-469.e7
Effect of Raloxifene on All-cause Mortality
- 1 May 2010
- Published by Elsevier in The American Journal of Medicine
- Vol. 123 (5) , 469.e1-469.e7
Effect of Raloxifene on All-cause Mortality
- 1 September 2009
- Published by Wolters Kluwer Health in Menopause
- Vol. 16 (5) , 932-936
Is a shorter hot flash diary just as good as a 7-day diary?
In randomized trials, the most common way to measure the effect of treatment on the frequency and severity of menopausal hot flashes is a 7-day self-reported diary. However, adherence with completing the hot flash diary in real time may be poor, and completing a diary is cumbersome for study participants. Our objective was to determine if a shorter diary for recording self-reported hot flashes is as accurate and precise as the traditional 7-day diary. Using cross-sectional data from a multicenter randomized clinical trial of an herbal preparation (MF101, an estrogen receptor β-selective agonist for treatment of menopausal hot flashes), we compared findings based on shorter diaries with findings based on a 7-day diary. With 3 days of diary keeping, the mean number of hot flashes per day and mean severity were almost identical to the means based on the 7-day diary, the SDs of the means were almost identical, and the intraclass correlations were almost perfect. The difference in the mean number of hot flashes per day compared with the 7-day diary was only 12% of one hot flash. Data from a different clinical trial revealed similar correspondence between the findings of a 3- and 7-day diary. In our study, the optimal duration of diary keeping to record menopausal hot flashes seems to be 3 days. In addition to being as good as a 7-day diary, a 3-day diary would be less burden on study participants and research staff and less expensive.
- 1 September 2009
- Published by Wolters Kluwer Health in Menopause
- Vol. 16 (5) , 932-936
Is a shorter hot flash diary just as good as a 7-day diary?
In randomized trials, the most common way to measure the effect of treatment on the frequency and severity of menopausal hot flashes is a 7-day self-reported diary. However, adherence with completing the hot flash diary in real time may be poor, and completing a diary is cumbersome for study participants. Our objective was to determine if a shorter diary for recording self-reported hot flashes is as accurate and precise as the traditional 7-day diary. Using cross-sectional data from a multicenter randomized clinical trial of an herbal preparation (MF101, an estrogen receptor β-selective agonist for treatment of menopausal hot flashes), we compared findings based on shorter diaries with findings based on a 7-day diary. With 3 days of diary keeping, the mean number of hot flashes per day and mean severity were almost identical to the means based on the 7-day diary, the SDs of the means were almost identical, and the intraclass correlations were almost perfect. The difference in the mean number of hot flashes per day compared with the 7-day diary was only 12% of one hot flash. Data from a different clinical trial revealed similar correspondence between the findings of a 3- and 7-day diary. In our study, the optimal duration of diary keeping to record menopausal hot flashes seems to be 3 days. In addition to being as good as a 7-day diary, a 3-day diary would be less burden on study participants and research staff and less expensive.
- 1 May 2009
- Published by Wolters Kluwer Health in Menopause
- Vol. 16 (3) , 458-465
MF101, a selective estrogen receptor β modulator for the treatment of menopausal hot flushes
To determine the optimal dose, safety, and efficacy of an estrogen receptor beta selective Chinese herbal extract, menopausal formula 101 (MF101), for treating hot flushes. A randomized, blinded trial in 217 postmenopausal women with hot flushes randomized to 5 or 10 g/day of MF101 or placebo for 12 weeks. The effects of 5 g/day of MF101 did not differ from those of placebo. After 12 weeks, the mean percent decrease in frequency of hot flushes in the 10 g/day group was 12.9% greater than that in the placebo group (P = 0.15), the median percent decrease was 11.7% greater than that in the placebo group (P = 0.05), and the proportion of women with at least a 50% reduction in hot flushes was 16.2% greater than that in the placebo group (P = 0.03). Treatment with 10 g/day of MF101 reduces the frequency of hot flushes. Trials with higher doses are planned.
- 1 May 2009
- Published by Wolters Kluwer Health in Menopause
- Vol. 16 (3) , 458-465
MF101, a selective estrogen receptor β modulator for the treatment of menopausal hot flushes
To determine the optimal dose, safety, and efficacy of an estrogen receptor beta selective Chinese herbal extract, menopausal formula 101 (MF101), for treating hot flushes. A randomized, blinded trial in 217 postmenopausal women with hot flushes randomized to 5 or 10 g/day of MF101 or placebo for 12 weeks. The effects of 5 g/day of MF101 did not differ from those of placebo. After 12 weeks, the mean percent decrease in frequency of hot flushes in the 10 g/day group was 12.9% greater than that in the placebo group (P = 0.15), the median percent decrease was 11.7% greater than that in the placebo group (P = 0.05), and the proportion of women with at least a 50% reduction in hot flushes was 16.2% greater than that in the placebo group (P = 0.03). Treatment with 10 g/day of MF101 reduces the frequency of hot flushes. Trials with higher doses are planned.
- Open Access
- 10 June 2008
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 100 (12) , 854-861
Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk
In the Raloxifene Use for The Heart trial, 10 101 postmenopausal women with coronary heart disease (CHD) or multiple CHD risk factors were randomly assigned to 60 mg/d raloxifene or to placebo and followed for a median of 5.6 years. Raloxifene, a selective estrogen receptor modulator, was found to reduce the risk of invasive breast cancer and vertebral fractures but not the risk of cardiovascular events. Here, we provide further details about breast cancer incidence by tumor characteristics, duration of treatment, and subgroup. Reported breast cancer was adjudicated by an independent committee based on medical records and pathology reports. The primary analyses used Cox proportional hazards models with time to first breast cancer as the outcome. Subgroup effects were analyzed using similar models with terms for treatment by subgroup. All statistical tests were two-sided. As previously reported, raloxifene reduced the incidence of invasive breast cancer by 44% (hazard ratio [HR] = 0.56; 95% confidence interval [CI] = 0.38 to 0.83; absolute risk reduction = 1.2 invasive breast cancers per 1000 women treated for 1 year). The lower incidence of invasive breast cancer reflected a 55% lower incidence of invasive estrogen receptor (ER)–positive tumors (HR = 0.45; 95% CI = 0.28 to 0.72). However, raloxifene treatment did not reduce the incidence of noninvasive breast cancer or of invasive ER-negative breast cancer. The reduced incidence of invasive breast cancer was similar across subgroups, including those defined by age, body mass index, family history of breast cancer, prior use of postmenopausal hormones, and 5-year estimated risk of invasive breast cancer. Raloxifene reduces risk of invasive ER-positive breast cancer regardless of a woman’s baseline breast cancer risk but does not reduce risk of noninvasive or ER-negative breast cancers. These results confirm those of the Multiple Outcomes of Raloxifene Evaluation, a previous randomized trial among women with osteoporosis.
- 10 June 2008
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 100 (12) , 854-861
Open AccessReduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk
In the Raloxifene Use for The Heart trial, 10 101 postmenopausal women with coronary heart disease (CHD) or multiple CHD risk factors were randomly assigned to 60 mg/d raloxifene or to placebo and followed for a median of 5.6 years. Raloxifene, a selective estrogen receptor modulator, was found to reduce the risk of invasive breast cancer and vertebral fractures but not the risk of cardiovascular events. Here, we provide further details about breast cancer incidence by tumor characteristics, duration of treatment, and subgroup. Reported breast cancer was adjudicated by an independent committee based on medical records and pathology reports. The primary analyses used Cox proportional hazards models with time to first breast cancer as the outcome. Subgroup effects were analyzed using similar models with terms for treatment by subgroup. All statistical tests were two-sided. As previously reported, raloxifene reduced the incidence of invasive breast cancer by 44% (hazard ratio [HR] = 0.56; 95% confidence interval [CI] = 0.38 to 0.83; absolute risk reduction = 1.2 invasive breast cancers per 1000 women treated for 1 year). The lower incidence of invasive breast cancer reflected a 55% lower incidence of invasive estrogen receptor (ER)–positive tumors (HR = 0.45; 95% CI = 0.28 to 0.72). However, raloxifene treatment did not reduce the incidence of noninvasive breast cancer or of invasive ER-negative breast cancer. The reduced incidence of invasive breast cancer was similar across subgroups, including those defined by age, body mass index, family history of breast cancer, prior use of postmenopausal hormones, and 5-year estimated risk of invasive breast cancer. Raloxifene reduces risk of invasive ER-positive breast cancer regardless of a woman’s baseline breast cancer risk but does not reduce risk of noninvasive or ER-negative breast cancers. These results confirm those of the Multiple Outcomes of Raloxifene Evaluation, a previous randomized trial among women with osteoporosis.
Postmenopausal hormone therapy
Footnotes Competing interests: DG has received research support from Berlex, Bionovo, Eli Lilly, and Pfizer. EB-C has received research support from NIH, Amgen, Lilly, Merck, Wyeth, Proctor and Gamble, Roche, and GlaxoSmithKline. Provenance and peer review: Commissioned; not externally peer reviewed.
Postmenopausal hormone therapy
Footnotes Competing interests: DG has received research support from Berlex, Bionovo, Eli Lilly, and Pfizer. EB-C has received research support from NIH, Amgen, Lilly, Merck, Wyeth, Proctor and Gamble, Roche, and GlaxoSmithKline. Provenance and peer review: Commissioned; not externally peer reviewed.